ORKA vs GEMI Comparison

Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.

Gemini Space Station Inc is engaged on unlocking the next era of financial, creative, and personal freedom. It envisions a future where crypto will redesign the global financial system, the internet, and money in a way that provides greater choice, independence, and opportunity for all. As a trusted bridge between the traditional financial system and the emerging crypto economy, It is providing access for individuals and institutions to a decentralized future that is more open, fair, and secure. Its core exchange product has expanded over time to become a comprehensive platform for its users to engage with the crypto economy, including a derivatives exchange, staking services, an over-the-counter (OTC) trading desk, institutional-grade custody, and others.